Context Therapeutics' CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer

Designation highlights potential to address unmet need for patients with PROC

Apr. 2, 2026 at 11:50am

Got story updates? Submit your updates here. ›

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (PROC) in patients that have received all standard of care therapies. The company is currently evaluating CTIM-76 in a Phase 1 clinical trial and expects to share interim data in June 2026.

Why it matters

The FDA's Fast Track Designation is intended to expedite the development and review of drugs that demonstrate the potential to treat serious conditions and address unmet medical needs. This designation for CTIM-76 highlights its potential to improve outcomes for patients with platinum-resistant ovarian cancer, a difficult-to-treat form of the disease with limited treatment options.

The details

Context Therapeutics is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to assess the safety and efficacy of the drug in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The trial will evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody, with CLDN6 being enriched in a variety of solid tumors. Preclinical research suggests CTIM-76 has the potential for convenient dosing, low immunogenicity risk, and scalable manufacturing.

  • Context Therapeutics expects to share interim data for the CTIM-76 Phase 1 trial in June 2026.

The players

Context Therapeutics Inc.

A clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors.

Karen Chagin, M.D.

Chief Medical Officer of Context Therapeutics.

CTIM-76

A CLDN6 x CD3 T cell engaging bispecific antibody being developed by Context Therapeutics for the treatment of platinum-resistant ovarian cancer.

U.S. Food and Drug Administration (FDA)

The regulatory agency that granted Fast Track Designation to CTIM-76 for the treatment of platinum-resistant ovarian cancer.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to receive Fast Track Designation for CTIM-76, which underscores its potential to improve the lives of patients with platinum-resistant ovarian cancer.”

— Karen Chagin, M.D., Chief Medical Officer of Context Therapeutics

What’s next

Context Therapeutics expects to share interim data from the CTIM-76 Phase 1 trial in June 2026.

The takeaway

The FDA's Fast Track Designation for CTIM-76 highlights the potential of this T cell engaging bispecific antibody to address the significant unmet need for new treatment options for patients with platinum-resistant ovarian cancer, a difficult-to-treat form of the disease.